Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study-Reference-Cited by-同舟云学术

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study

Published:2010-07-27 Issue:11 Volume:95 Page:1913-1920
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Lahuerta J. J.,Mateos M. V.,Martinez-Lopez J.,Grande C.,de la Rubia J.,Rosinol L.,Sureda A.,Garcia-Larana J.,Diaz-Mediavilla J.,Hernandez-Garcia M. T.,Carrera D.,Besalduch J.,de Arriba F.,Oriol A.,Escoda L.,Garcia-Frade J.,Rivas-Gonzalez C.,Alegre A.,Blade J.,San Miguel J. F.,

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT;Bone Marrow Transplantation;2024-01-31

2. Reduced-dose carmustine (300 mg/m2) and melphalan as a conditioning regimen in multiple myeloma patients with CNS involvement: A case series;Current Problems in Cancer: Case Reports;2023-12

3. Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment;Journal of Clinical Medicine;2023-09-27

4. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT;2023-09-22

5. Melphalan-loaded methoxy poly(ethylene glycol)-poly(d,l-lactide) copolymer nanomicelles in the treatment of multiple myeloma;Chinese Chemical Letters;2023-09